<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987750</url>
  </required_header>
  <id_info>
    <org_study_id>Z7219L04</org_study_id>
    <nct_id>NCT03987750</nct_id>
  </id_info>
  <brief_title>Safinamide for Levodopa-induced Dyskinesia (PD-LID)</brief_title>
  <official_title>A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, multi-center, randomized, double-blind, parallel group,
      placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic
      medication and have at least mild levodopa-induced dyskinesia. Eligible participants will be
      randomized to one of three treatment groups to receive adjunctive daily treatment with either
      safinamide 100 mg, safinamide 150 mg or placebo in a 1:1:1 ratio. Outcome will be assessed
      after 26 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial participation will be up to a maximum duration of 32 weeks and will comprise:

        -  Screening period (up to 4 weeks) for screening assessments;

        -  Two weeks titration period: participants randomized to the 100 mg study arm will receive
           100 mg during Week 1 and throughout the rest of the study; participants randomized to
           the 150 mg study arm will receive 100 mg during Weeks 1 and 2 , and 150 mg from Week 3
           and throughout the rest of the study; participants randomized to the placebo arm will
           receive identical placebo tablets.

        -  Twenty-four weeks maintenance period during which patients receive their randomized
           treatment as an adjunct to their standard anti-PD medications, which should remain
           unaltered. End of treatment evaluations will be performed at the end of Week 26 or at
           early discontinuation

        -  A telephone follow-up call will be performed 2 weeks after the end of treatment to
           assess adverse events and concomitant medications
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    drug development plan has been updated
  </why_stopped>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of two doses of safinamide on reducing levodopa-induced dyskinesia</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline to Week 26 in levodopa-induced dyskinesia based on UDysRS total score. The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of two doses of safinamide on ON time with No Dyskinesia</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (Day 1 prior to start of study intervention) to Week 26 total daily ON time with No dyskinesia based on PD Home Diary. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of two doses of safinamide on ON time with non-troublesome dyskinesia</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with non-troublesome dyskinesia. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of two doses of safinamide on ON time with troublesome dyskinesia</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with troublesome dyskinesia. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on ON time with any dyskinesia (troublesome or non-troublesome)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with any dyskinesia (troublesome or non-troublesome). A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on sleep time</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily sleep time. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score and sub-scores</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (Day 1 prior to start of study intervention) to Week 26 in MDS-UPDRS total score and sub-scores. The MDS-UPDRS is divided into 4 parts. In each part, all items are rated on a scale from 0 (normal) to 4 (severe impairment); Part I assesses 15 items of non-motor aspects of experiences of daily living; Part II comprises 13 items evaluating the impact of PD on patients' activities of daily living (ADL) over the week prior to the visit such as speech, salivation, swallowing, eating, handwriting, dressing, turning in bed, walking; part III assesses the motor abilities in PD patients at the time of the visit; Part IV assesses motor complications of therapy, such as dyskinesias, motor fluctuations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on Clinician Global Impression of Change (CGIc)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Clinician Global Impression of Change (CGIc) at Week 26. CGI-C is a 7-point scale used by Investigator to rate patient's overall improvement using a range of responses from 1 (very much improved) through to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on Patient Global Impression of Change (PGIc)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Patient Global Impression of Change (CGIc) at Week 26. PGI-C is a 7-point scale depicting a patient's rating of overall improvement using a range of responses from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of two doses of safinamide on PDQ-39 summary index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from Baseline (Day 1 prior to start of study intervention) to Week 26 in PDQ-39 summary index. The PDQ-39 is a specific tool to assess quality of life in PD. Comprises 39 items divided into eight dimensions: mobility, activities of daily living (ADLs), emotional well-being, stigma, social support, cognition, communication and physical discomfort, where scores range from 0-100, with the higher, the worse the perception of quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dyskinesia, Drug-Induced</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Safinamide 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safinamide 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide Methanesulfonate 150mg</intervention_name>
    <description>150 mg (free base)</description>
    <arm_group_label>Safinamide 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide Methanesulfonate 100mg</intervention_name>
    <description>100 mg (free base)</description>
    <arm_group_label>Safinamide 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide Methanesulfonate matching placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female participants aged 30 years and above at the time of signing the
             informed consent;

          2. Female participants may participate if they are not of child bearing potential
             (post-menopausal with no periods for at least one year, or surgically sterilized);

          3. Women of child bearing potential (WOCBP) may participate if they are not pregnant, not
             breastfeeding, and agree to follow the contraceptive guidance during the treatment
             period and for at least 30 days after the last dose of study intervention;

          4. A diagnosis of Parkinson's disease consistent with the UK PD Brain Bank Society and
             MDS Clinical Diagnostic Criteria;

          5. Levodopa immediate release and/or controlled release, given at least 3 times daily, on
             a stable regimen for at least 4 weeks prior to screening;

          6. Participants may also be taking benserazide, catcechol O methyl transferease (COMT)
             inhibitors and dopamine agonists, the dose of which must be stable for at least 4
             weeks prior to screening;

          7. Predictable peak dose dyskinesia of at least mild severity and causing at least mild
             disability as defined as a score of â‰¥2 on the MDS UPDRS questions 4.1 and 4.2 at
             screening and at least two 30 minute periods of ON time with troublesome dyskinesia
             recorded in 24 hour PD home diaries performed in each of the two days prior to the
             randomization visit;

          8. Participants with motor fluctuations with at least three 30 minute periods in OFF (for
             a total of 1.5 hours per waking day) in each of the two consecutive 24 hour home
             diaries completed at the end of the screening period in the 48 hours prior to Day 1

          9. Provided written informed consent as described in Appendix 1 which includes compliance
             with the requirements and restrictions listed in the informed consent form (ICF) and
             in this protocol, prior to the study screening procedures commencing.

        Exclusion Criteria:

          1. Participants with secondary or atypical parkinsonian syndrome

          2. Participants with solely diphasic dyskinesia without peak dose dyskinesia

          3. History of neurosurgical procedure for Parkinson's disease, including stereotactic
             surgery and Deep Brain Stimulation (DBS).

          4. Treatment with monoamine oxidase inhibitors, amantadine pethidine, dextromethorphan,
             fluoxetine, fluvoxamine in the 8 weeks prior to the screening visit

          5. Concomitant use of selective serotonin reuptake inhibitors (SSRIs), serotonin
             norepinephrine reuptake inhibitors (SNRIs), tricyclic/tetracyclic antidepressants may
             be permitted but used at the lowest doses.

          6. Participants who are unable to complete the home diary and have 2 consecutive 24-hour
             periods with more than 4 missing periods per 24 hours in the diary, completed at the
             end of the screening period, in the 48 hours prior to Day 1

          7. History of major psychiatric disease eg bipolar disorder, severe depression,
             schizophrenia or other psychosis.

          8. Current history of Impulse Control Disorder

          9. History of drug and/or alcohol abuse within 12 months prior to screening (DSM-V
             criteria)

         10. History of dementia (DSM-V criteria) or cognitive impairment MMSE &lt; 24 at screening

         11. Ophthalmologic history of the following conditions: albinism, uveitis, retinitis
             pigmentosa, retinal degeneration, active retinopathy, severe progressive diabetic
             retinopathy, inherited retinopathy or family history of hereditary retinal disease.

         12. Moderate or severe hepatic impairment with transaminases &gt;2 times upper limit of
             normal (ULN) or bilirubin 1.5 times ULN

         13. Any clinically significant or unstable medical or surgical condition that, in the
             opinion of the investigator, might preclude safe completion of the study or might
             affect the results of the study.

         14. Use of any investigational drug within 30 days prior to screening or 5 half-lives,
             whichever is the longest.

         15. Allergy/sensitivity or contraindications to the investigational medicinal product
             (IMP) or their excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Keywood, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zambon SpA</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Dyskinesia, Drug-Induced</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

